Monday, December 12, 2016

BRIEF-EU grants Genmab marketing approval for Arzerra combination

* European Commission grants marketing authorisation for

Arzerra (Ofatumumab) in combination with Fludarabine and

Cyclophosphamide for treatment of adult patients with

relapsed chronic lymphocytic leukemia (CLL)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)